NCT02932007

Chloroquine for Patients With Symptomatic Persistent Atrial Fibrillation: A Prospective Pilot Study

• Status: Recruiting
• Phase: Phase 2
• Study type: Interventional
• Enrollment: 40 (estimated)
• Sponsor: University of South Florida · Academic / Other
• Sex: All
• Age: 18 Years
• Healthy volunteers: Not accepted

Summary

The goal of this pilot study is to explore the efficacy of chloroquine in terminating persistent AF and assess its potential role as a pharmacological cardioversion agent for the management of AF.

Detailed description

This is an open-label, pilot study to explore the efficacy of chloroquine in terminating persistent AF within 2 weeks of drug administration and assess its potential role as a pharmacological cardioversion agent for the management of AF. Subjects will be followed for 2 weeks from the start of drug administration to study drug termination.

Conditions

• Atrial Fibrillation

Interventions

Type	Name	Description
DRUG	Chloroquine Phosphate	Two tablets of study drug are to be taken on the day of study drug initiation and the next day, followed by one tablet each day for the next 12 days. Study drug to be orally administered and taken with food.

Timeline

• Start date: 2017-03-28
• Primary completion: 2020-03-01
• Completion: 2020-09-01
• First posted: 2016-10-13
• Last updated: 2019-08-19

Locations

1 site across 1 country: United States

Regulatory

• FDA-regulated drug study